The original disclosure in Japanese was released on February 10, 2022 at 15:00 (GMT +8)
Note: This document has been translated from the Japanese original for reference purposes only. In the event ofany discrepancy between this translated document and the Japanese original, the original shall prevail.

February 10, 2022
Company
Headquarters
Representative
Contact
Telephone
WebsiteTakara Bio Inc. (First Section TSE, code: 4974)
Nojihigashi 7-4-38, Kusatsu, Shiga, Japan
Koichi Nakao, President & CEO
Takuya Kakemi, Executive Officer, Head ofCorporate Management Division(+81)77-565-6970
https://www.takara-bio.co.jp/

Notice Concerning Forecast Revisions of Financial Results and Dividend (Dividend Increase)

Takara Bio Inc. (Takara Bio), announced the revisions of the consolidated financial results forecast and thedividend forecast for the fiscal year ending March 31, 2022 (April 1, 2021 – March 31, 2022) that was disclosed
on November 9, 2021, as follows based on a review of current trends in results of operations.

1. Revision of Financial Forecast(1) Revision of the consolidated forecast for the fiscal year ending March 2022 (April 1, 2021 – March 31,2022)
Net sales

Operatingprofit

Ordinaryprofit

Net income
attributable toowners of parent

Net income
per share

Million yen

Million yen

Million yen

Million yen

Yen

Previous forecast (A)59,30020,00020,20014,100117.09

Revised forecast (B)65,00026,00026,20018,500153.63

Amount of change (B-A)

5,700

6,000

6,000

4,400

-

Percentage of Change (%)

9.6

30.0

29.7

31.2

-

46,086

13,952

14,159

9,547

79.29

(Reference) Results for theprevious fiscal year ended
March 31, 2021

(2) Reasons for the Revision
Gross profit, operating profit, ordinary profit, and net income attributable to owners of parent are also
expected to exceed the previously announced forecasts due to sales of new Coronavirus PCR testing
reagents and general research reagents exceeding the previously announced forecasts for Reagents, as well
as a further decline in the cost of sales ratio due to changes in the sales mix and improved production

The original disclosure in Japanese was released on February 10, 2022 at 15:00 (GMT +8)
utilization rates. Therefore, the forecast of consolidated financial results for the full fiscal year has beenrevised.
For details of the forecasts announced this time, please refer to page 12 of the "Consolidated Financial
Statements for the Third Quarter Ended December 31, 2021. FY2022 (April 1, 2021 – March 31, 2022)[UNAUDITED]" announced today.

2. Revision of Dividend Forecast(1) Details of Revised Dividend Forecast
Record Date
Previous forecast(Disclosed on Nov. 9, 2021)
Revised forecast
Actual results
Results for the previous fiscal
year ended March 31, 2021

Cash dividends per share (yen)End of 2 quarter
Year-end24.00 yenndTotal24.00 yen

30.00 yen

30.00 yen

16.00 yen

16.00 yen

0.00 yen
0.00 yen(2) Reasons for the Revision
Considering the management performance and financial statement comprehensively, Takara Bio recognizes abasic policy aimed for profit contribution, positioning an important business management issue to distributeprofits to shareholders as well as enhancing the internal reserves to strengthen the research development
activities in Bioindustry and Gene Therapy businesses. Specifically, the dividends of surplus will be paid ataround 20% of estimated profit calculated without considering extraordinary gain or loss in the consolidated
financial statements.
Based on the above upward revision of the full-year consolidated financial forecast and the above
shareholder return policy, Takara Bio has revised the year-end dividend forecast for the year ending March2022 from 24.00 to 30.00 per share.
The year-end dividend for the fiscal year ending March 31, 2022 is scheduled to be discussed at the 20th
Ordinary General Meeting of Shareholders to be held in June 2022.

Forward-Looking Statements
Statements contained in these materials with respect to the Company’s current plans, forecasts, strategies and beliefs thatare not historical facts are forward-looking statements about the further performance of the Company and its consolidated
subsidiaries. These statements are based on management’s assumptions and beliefs in light of information currently
available to it, but are based on a number of assumptions and beliefs derived from information that contains significant
risks and uncertainties. Actual results may differ materially from these forecasts due to various factors. Factors that could
influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as
well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors’ prices and productstrategies, declines in selling power of the Company’s existing and new products, disruptions to production, violations of
our intellectual property rights, rapid advances in technology, and unfavorable verdicts in major litigation.